Core Insights - Company Junsheng Tai Pharmaceutical-B (02511) presented data on HTD1801 at the 58th American Society of Nephrology (ASN) annual meeting, highlighting its potential benefits for patients with mild renal impairment [1] - HTD1801 is a first-in-class anti-inflammatory metabolic modulator (AIMM) designed to address cardiorenal metabolic system diseases (CKM) through a dual mechanism of activating AMPK and inhibiting NLRP3 [1] Clinical Results - The clinical results indicate that HTD1801 significantly improves eGFR in patients with mild renal impairment compared to placebo, with a positive slope in eGFR during treatment [2] - In patients with hyperfiltration, HTD1801 was associated with a reduction in eGFR compared to placebo, suggesting its potential to promote the restoration of normal kidney function [2] - HTD1801 did not show adverse effects on blood pressure, blood sodium, or blood potassium levels [2] Study Design - The data presented is based on a pooled analysis from two Phase III randomized, double-blind, placebo-controlled clinical studies (SYMPHONY1 & 2; N=956) conducted in patients with type 2 diabetes (T2DM) [1] - The analysis included post-hoc evaluations of subgroups with mild renal impairment (baseline eGFR: 60-90 ml/min/1.73m²) and hyperfiltration (baseline eGFR ≥120 ml/min/1.73m²), focusing on eGFR changes as the primary endpoint [1]
2025 ASN最新突破性专场|君圣泰医药-B展示HTD1801肾脏获益数据